Er.12.0220.1.162.08.0.0.0 1650rpm 3ph

About Fibrotor

Fibrotor is a specialized biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of fibrotic diseases, with a particular focus on idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). The company's lead product candidate, FTR-125, is an oral selective inhibitor of dipeptidyl peptidase 4 (DPP4), which is being evaluated in clinical trials for the potential to slow disease progression and improve quality of life for patients with IPF. Fibrotor's mission is to advance science and provide hope for those affected by fibrotic diseases, with a commitment to rigorous research, development, and collaboration with the broader medical community.